中国生物制药(01177.HK):甲磺酸艾立布林注射液已获得中国国家药品监督管理局的上市批准,用于治疗既往接受过至少两种

美港电讯
11 Dec 2024

中国生物制药(01177.HK):甲磺酸艾立布林注射液已获得中国国家药品监督管理局的上市批准,用于治疗既往接受过至少两种化疗方案(含蒽环类和紫杉烷类药物)的局部晚期或转移性乳腺癌患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10